Stockscreener 앱 받기
53.34
16.08%
7.39
Crinetics Pharmaceuticals Inc 주식(CRNX)의 최신 뉴스
Crinetics Pharma CCO Kalofonos sells $137,500 in shares By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals’ Positive Trial Results and Stock Target Uplift Spark Optimism - StocksToTrade
Crinetics Announces Major Public Offering to Fund Growth - TipRanks
Crinetics Pharmaceuticals Announces Public Offering of Common Stock - TradingView — Track All Markets
Crinetics Pharmaceuticals announces $350M proposed public offering - MSN
Crinetics (CRNX) Sees Significant Stock Price Increase - GuruFocus
Crinetics Shares Rise After Pricing $350 Million Stock Offering - MarketScreener
CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial - Asianet Newsable
Crinetics Pharmaceuticals’ Stock Surges after Positive Trial Results and Analyst Boosts - timothysykes.com
Crinetics (CRNX) shares jump as $350 million stock sale clears and early PALSONIFY revenue hits - TechStock²
Crinetics (CRNX) Stock Soars Over 12% Amid Market Activity - GuruFocus
Why Crinetics Pharmaceuticals Shares Are Sinking Today - TipRanks
Crinetics Pharma climbs after $350 mln stock sale - TradingView — Track All Markets
Crinetics Pharmaceuticals (CRNX) Stock Analysis: A Deep Dive Into 71% Upside Potential - DirectorsTalk Interviews
Crinetics Prices $350 Million Stock Offering - marketscreener.com
Crinetics Pharmaceuticals prices offering at $45.95 per share - MSN
Crinetics Pharmaceuticals prices public offering at $45.95 per share - Investing.com India
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock - The Manila Times
Crinetics Pharmaceuticals prices public offering at $45.95 per share By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals Prices Public Offering of 7.62 Million Shares at $45.95 Each, Anticipating $350 Million in Proceeds - Quiver Quantitative
Crinetics Pharmaceuticals prices public offering of 7.6 million shares at $45.95 each - MarketScreener
Crinetics Prices 7.62M Share Offering at $45.95, Raising $350M - Intellectia AI
Crinetics Pharmaceuticals Inc. (CRNX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 8.2%Here's What Happened - MarketBeat
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Exact Sciences (EXAS) - The Globe and Mail
CRNX Stock: Morgan Stanley Raises Price Target to $80 | CRNX Sto - GuruFocus
Morgan Stanley Increases Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $80.00 - MarketBeat
Early PALSONIFY Launch and Atumelnant Data Might Change The Case For Investing In Crinetics (CRNX) - simplywall.st
Crinetics Pharmaceuticals shares down 6.4% after announcing $350 million stock offering - MarketScreener
Crinetics stock outperforms with strong Palsonify sales, Oppenheimer reiterates $87 target - Investing.com Nigeria
Crinetics stock maintains Buy rating at H.C. Wainwright on strong CAH data - Investing.com
Crinetics Pharma ticks down after announcing $350 mln stock offering - TradingView — Track All Markets
Crinetics Pharmaceuticals plans $350 million stock offering By Investing.com - Investing.com Nigeria
Crinetics reports over $5 million in Q4 revenue from acromegaly drug - Investing.com Nigeria
Crinetics Pharmaceuticals stock hits 52-week high at 55.23 USD - Investing.com
Crinetics Buy Rating: Derisked Atumelnant CAH Program and Outperforming Palsonify Launch Signal Undervalued Shares - TipRanks
Crinetics Pharmaceuticals Stock: Biotech Optimism Meets Volatile Reality - AD HOC NEWS
Crinetics shares jump on robust PALSONIFY uptake and encouraging trial results - MSN
Crinetics stock soars after strong PALSONIFY launch and positive trial data - Investing.com
Crinetics plans $350 mln public share offering - MSN
Crinetics Reports Strong Palsonify Launch To Date, Positive Phase II CAH Data - Citeline News & Insights
Crinetics Pharmaceuticals announces proposed public offering of common stock - MarketScreener
Crinetics Highlights Strong PALSONIFY Launch and Trial Progress - TipRanks
Crinetics Pharmaceuticals Plans $350 Million Public Offering - MarketScreener
Crinetics Pharmaceuticals plans $350 million stock offering - Investing.com India
Crinetics stock ticks lower after announcing $350 million public offering By Investing.com - Investing.com South Africa
Crinetics stock ticks lower after announcing $350 million public offering - Investing.com
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock - The Manila Times
CRNX stock gains, NBIX shares drop on positive results from genetics disorder trial - MSN
Crinetics Pharmaceuticals’ Latest Trial Sparks Market Movement - StocksToTrade
Crinetics stock price target raised to $80 from $77 at Morgan Stanley - Investing.com Nigeria
Crinetics stock price target raised to $97 from $85 at Jones Trading - Investing.com
Baird reiterates Outperform rating on Crinetics stock as Palsonify launch exceeds expectations - Investing.com
Crinetics reports robust full-quarter sales for rare disease drug Palsonify - Endpoints News
28.63%
자본화:
|
볼륨(24시간):